Oaktree Acquisition Corp. III Life Sciences Reports Officer and Director Changes

TL;DR

Oaktree III Life Sciences shakes up leadership, new directors and officers appointed.

AI Summary

Oaktree Acquisition Corp. III Life Sciences filed an 8-K on January 7, 2025, reporting changes effective January 6, 2025. These changes include the departure of directors or certain officers, the election of new directors, and the appointment of certain officers. The filing also addresses compensatory arrangements for certain officers.

Why It Matters

This filing indicates significant changes in the company's leadership and governance structure, which could impact strategic direction and operational oversight.

Risk Assessment

Risk Level: medium — Changes in directors and officers can signal shifts in strategy or internal dynamics that may affect the company's future performance.

Key Players & Entities

• Oaktree Acquisition Corp. III Life Sciences (company) — Registrant
• January 6, 2025 (date) — Effective date of reported changes
• January 7, 2025 (date) — Filing date of the 8-K

FAQ

Key Financial Figures

• $0.0001 — nsisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeema
• $11.50 — ordinary share at an exercise price of $11.50 OACCW The Nasdaq Stock Market LLC

Filing Documents

• d920585d8k.htm (8-K) — 19KB
• 0001193125-25-002863.txt ( ) — 20KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 6, 2025 Oaktree Acquisition Corp. III Life Sciences (Exact name of registrant as specified in its charter) Cayman Islands 001-42383 98-1799512 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 333 South Grand Avenue, 28th Floor Los Angeles, California 90071 (Address of principal executive offices) (Zip Code) +1 (213) 830-6300 (Registrants telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeemable warrant OACCU The Nasdaq Stock Market LLC Class A ordinary shares included as part of the units OACC The Nasdaq Stock Market LLC Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 OACCW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 6, 2025, John Frank resigned from the board of directors (the Board) of Oaktree Acquisition Corp. III Life Sciences (the Company). In connection with Mr. Franks resignation, the Board appointed (i) Aman Kumar, currently a director of the Company, as the new chairman of the Board, and (ii) Zaid Pardesi, the Companys Chief Executive Officer, as a director of the Company. Mr. Pardesi will serve on the Board as a Class III director whose term will expire at the Companys third annual meeting of shareholders. Mr. Franks resignation was not the result of any disagreement with the Company on any matter relating to the Companys operations, policies or practices. There are no arrangements or understandings between Mr. Pardesi and any other persons pursuant to which Mr. Pardesi was appointed as director of the Company. There are also no family relationships between Mr. Pardesi and any director or executive officer of the Company. As previously disclosed in the Companys final prospectus (the Final Prospectus), filed with the U.S. Securities and Exchange Commission on October 24, 2024 in connection with the consummation of the Companys initial public offering (the Initial Public Offering), Zaid Pardesi and Aman Kumar may be considered to have a material interest in Oaktree Acquisition Holdings III LS, LLC (the Sponsor), which entered into a series of transactions with the Company in connection with the Initial Public Offering. Mr. Pardesi has no direct or indirect interest in any transaction or proposed transaction that was not previously disclosed pursuant to Item 404(a) of Regulation S-K under the section Certain Relationships and Related Party Transactions in the Final Prospectus. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 7, 2025 OAKTREE ACQUISITION CORP. III LIFE SCIENCES By: /s/ Zaid Pardesi Name: Zaid Pardesi Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR